Management of poor-prognosis or relapsed germ-cell cancer

BJU International

Volumn 104, Issue 9 B, 2009, Pages 1392-1397

  Daugaard, Gedske ^a  

^a Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BEVACIZUMAB; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLATINUM; THALIDOMIDE; TOPOTECAN; VASCULOTROPIN RECEPTOR 1; VINBLASTINE;

CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GERM CELL TUMOR; HUMAN; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PALLIATIVE CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; TESTICULAR NEOPLASMS;

EID: 70350439575     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08865.x     Document Type: Review

References (62)

1. International Germ Cell Collaborative Group. International Germ Cell Classification: a prognostic factor-based staging system for metastatic germ-cell cancers. J Clin Oncol 1997 15 : 594 603
2. Kollmannsberger C, Nichols C, Bokemeyer C. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Cancer 2006 106 : 1217 1226
3. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology group protocol. J Clin Oncol 1991 9 : 1163 1172
4. Nichols CR, Catalano PJ, Crawford ED et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group and Cancer and Leukemia Group B study. J Clin Oncol 1998 16 : 1287 1293
5. Kaye SB, Mead GM, Fossa S et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol 1998 16 : 692 701
6. De Wit R, Stoter G, Sleijfer DT et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer 1995 71 : 1311 1314
7. Motzer RJ, Nichols CJ, Margolin KA et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous stem-cell rescue as first-line treatment for patients with poor prognosis metastatic germ cell cancer. J Clin Oncol 2007 25 : 247 256
8. Droz JP, Kramar A, Biron P et al. Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-Volume metastatic nonseminomatous germ-cell tumours; mature results of a randomized trial. Eur Urol 2007 51 : 739 746
9. Culine S, Kramar A, Theodore C et al. Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/ doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genitourinary Group of the French federation of Cancer Centers Trial T93MP. J Clin Oncol 2008 26 : 421 427
10. Zon RT, Nichols C, Einhorn LH. Management strategies and outcome of germ cell tumor patients with very high human chorionic gonadotropin levels. J Clin Oncol 1998 16 : 1294 1297
11. Christensen TB, Engbaek F, Marqversen J et al. 125I-labelled human chorionic gonadotrophin (hCG) as an elimination marker in the evaluation of hCG decline during chemotherapy in patients with testicular cancer. Br J Cancer 1999 80 : 1577 1581
12. Fizazi K, Culine S, Kramar A et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004 22 : 3868 3876
13. Beck SD. The role of postchemotherapy surgery in managing metastatic germ cell tumors. Cancer 2007 110 : 2601 2603
14. Fizazi K, Tjulandin S, Salvioni R et al. Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors. Prognostic factors and role of postsurgery chemotherapy. Results from an international study group. J Clin Oncol 2001 19 : 2647 2657
15. Fizazi K, Oldenburg J, Dunant A et al. Assessing prognosis and optimizing treatment in patients with post-chemotherapy viable non-seminomatous germ-cell tumors: results of the sCR2 International study. Ann Oncol 2008 19 : 259 264
16. Hartmann JT, Candelaria M, Kuczyk MA et al. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours. Eur J Cancer 1997 33 : 843 847
17. Besse B, Flechon A, Caty C et al. No need for contralateral lung surgery in case of evidence of post-chemotherapy necrosis alone in residual lung masses in patients with disseminated non seminomatous germ cell tumors. Proc Am Soc Clin Oncol 2005 23 : 383s
18. Rivoire M, Elias D, De Cian F et al. Multimodality treatment of patients with liver metastases from germ cell tumors. Cancer 2001 92 : 578 587
19. Beck SD, Foster RS, Bihrle R et al. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol 2005 23 : 6149 6156
20. Hartmann JT, Einhorn L, Nichols CR et al. Second-line chemotherapy in patients with relapsed extragonadal nonseminomatous germ cell tumors: results of an international multicenter analysis. J Clin Oncol 2001 19 : 1641 1648
21. Fosså SD, Bokemeyer C, Gerl A et al. Treatment outcome of patients with brain metastases from malignant germ cell tumors. Cancer 1999 85 : 988 997
22. Loehrer PJ, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998 16 : 2500 2504
23. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997 15 : 2559 2563
24. Pico JL, Rosti G, Kramer A et al. A randomized trial of high-dose chemotharapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumors. Ann Oncol 2005 16 : 1152 1159
25. Einhorn LH, Williams S, Abonour R. Salvage chemotherapy with high dose carboplatin + etoposide (HDCE) and peripheral blood stem cell transplant (PBSCT) in patients with germ cell tumors (GCT). J Clin Oncol 2006 24 : 4549a
26. Kondagunta GV, Bacik J, Donadio A et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors. J Clin Oncol 2005 23 : 6549 6555
27. Mardiak J, Salek T, Sycova-Mila Z et al. Paclitaxel plus ifosfamide and cisplatin in second-line treatment of germ cell tumors: a phase II study. Neoplasma 2005 52 : 497 501 (Pubitemid 41809409)
28. Mead GM, Cullen MH, Huddart R et al. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial. Br J Cancer 2005 93 : 178 184
29. Rick O, Beyer J, Kingreen D et al. High-dose chemotherapy in germ cell tumours: a large single centre experience. Eur J Cancer 1998 34 : 1883 1888
30. Sonpavde G, Hutson TE, Roth BJ. Management of recurrent testicular germ cell tumors. Oncologist 2007 12 : 51 61
31. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996 7 : 31 4
32. Einhorn LH, Stender MJ, Williams SD. Phase II trial of gemcitabine in refractory germ cell tumors. J Clin Oncol 1999 17 : 509 511
33. Bokemeyer C, Gerl A, Schoffski P et al. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 1999 17 : 512 516 (Pubitemid 29075236)
34. Hinton S, Catalano PJ, Einhorn L et al. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors. J Clin Oncol 2002 20 : 1859 1863
35. Einhorn LH, Brames MJ, Juliar B, Williams SD. Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant. J Clin Oncol 2007 25 : 513 516
36. Kollmannsberger C, Rick O, Derigs HG et al. Activity of oxilaplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German testicular Cancer Study Group. J Clin Oncol 2002 20 : 2031 2037 (Pubitemid 34408792)
37. Kollmannsberger C, Beyer J, Lietsch R et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 2004 22 : 108 114
38. Pectasides D, Pectasides M, Farmakis D et al. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 2004 15 : 493 497
39. Di Giorgi U, Rosti G, Aieta M et al. Phase II study of oxaliplatin and gemcitabine salvage chemotharpy in patients with cisplatin-refractory nonseminomatous germ cell tumor. Eur Urol 2006 50 : 1032 1038
40. Theodore C, Flechon A, Fizazi K et al. A phase II multicentre study of oxaliplatin (Ox) in combination with Paclitaxel (Px) in patients who failed cisplatin (CDDP) based chemotherapy for germ cell tumors. Proc Am Soc Clin Oncol 2004 23 : 389
41. Miki T, Mizutani Y, Nonomura N et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumours. Cancer 2002 95 : 1879 1885
42. Pectasides D, Pectasides M, Farmakis D et al. Oxaliplatin and irinotecan plus granulocyte stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol 2004 M46 : 216 222
43. Bokemeyer C, Kollmannsberger C, Meisner C et al. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors. A multivariate and matched-pair analysis. J Clin Oncol 1999 17 : 3450 3456
44. Einhorn LH, Williams SD, Chamness A et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007 357 : 340 348
45. Bokemeyer C, Oechsle K, Honecker F et al. Combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Study Group. Ann Oncol 2007 19 : 448 453
46. Izquierdo MA, van der Valk P, van Ark-Otte J et al. Differential expression of the c-kit proto-oncogene in germ cell tumours. J Pathol 1995 177 : 253 258
47. Madani A, Kemmer K, Sweeney C et al. Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 2003 14 : 873 880
48. Sakuma Y, Sakurai S, Oguni S et al. Alterations of the c-kit gene in testicular germ cell tumors. Cancer Sci 2003 94 : 486 491
49. Einhorn LH, Brames MJ, Heinrich MC et al. Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT. Am J Clin Oncol 2006 29 : 12 3
50. Pedersini R, Vattemi E, Mazzoleni G, Graiff C. Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. Lancet Oncol 2007 8 : 1039 1040
51. Hechelhammer I, Störkel S, Odermatt B et al. Epidermal growth factor receptor is a marker for syncytiotrophoblastic cell in testicular germ cell tumors. Virchows Arch 2003 443 : 28 31
52. Mandoky L, Geczi L, Bodrogi I et al. Expression of HER-2/neu in testicular tumors. Anticancer Res 2003 23 : 3447 3451
53. Olivarez D, Ulbright T, Deriese W et al. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994 54 : 2800 2802
54. Viglietto G, Romano A, Maglione D et al. Neovascularization in human germ cell tumors correlates with a marked increase in expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 1996 13 : 577 587
55. Rick O, Braun T, Siegert W, Beyer J. Activity of thalidomide in patients with platinum-refractory germ-cell tumors. Eur J Cancer 2006 42 : 1775 1779
56. Mego M, Reckova M, Sycova Mila Z et al. Bevacizumab in a growing teratoma syndrome. Case report. Ann Oncol 2007 18 : 962 963
57. Voigt W, Kegel T, Maher G et al. Bevazicumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third line salvage chemotherapy induced an unexpected dramatic response in highly platinum refratory germ cell cancer. Ann Oncol 2006 17 : 531 553
58. Olie RA, Looijenga LH, Boerrigter I et al. N- and K-RAS mutations in primary testicular germ cell tumors: incidence and possible biological implication. Genes Chromosomes Cancer 1995 12 : 110 116
59. Fenner MH, Beutel G, Grünwald V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs 2008 17 : 511 522
60. Fossa SD, Stenning SP, Gerl A et al. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999 80 : 1392 1399
61. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors. A multivariate analysis of prognostic variables. J Clin Oncol 1996 14 : 2638 2645 (Pubitemid 26329647)
62. Williams SD, Birch R, Einhorn L et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin and either vinblastine or etoposide. N Engl J Med 1987 316 : 1435 1440